PPARγ ligand treatment not only decreases the protein level of cyclin D1, but also increases the CDK inhibitors p21CIP and p27KIP1 through both increased transcriptional activity and inhibition of proteasome degradation in colorectal cancer cells [56, 57]. The gene discussed is PPARG; the disease is colorectal cancer.